Sirs,
We read with interest the work of the Psutka et al. 1 in their report on the surveillance of syphilis in New Zealand sexual health clinics, which describes a resurgence of acute syphilis, particularly among MSM and HIV-positive individuals. These remain the high prevalence groups in the UK, although we have seen a cluster of syphilis infections in young heterosexuals locally. 2 While the authors stated that this study did not reflect the prevalence of syphilis in the population outside of a sexual health clinic setting, we suspect that syphilis among clinic-attenders was also underrepresented. One criterion used by Psutka et al. to diagnose infectious syphilis was the presence of rapid plasma reagin tires of 1:32 or greater. The use of serology in diagnosing acute syphilis has limitations and repeat screening of high-risk individuals at six and 12 weeks after exposure is recommended. 3 The need for such individuals to re-attend is not always effectively communicated and high-risk patients often fail to return for testing and treponemal seroconversion may not be identified.
While Psutka et al. noted that the majority of those diagnosed with infectious syphilis had symptoms, the most common of which being genital ulceration and rash, it is not clear whether and to what extent dark ground microscopy (DGM) and/or PCR testing was used. Public Health England and BASHH recommend the use of DGM and PCR where possible. 3, 4 DGM is an effective point-of-care test in those with lesions of primary and secondary syphilis and an instant diagnosis can lead to immediate treatment and contact tracing. Expertise in DGM and the appropriate microscope may not be available in all sexual health clinics, particularly as many centres have adopted a 'hub and spoke' model whereby individuals with high sexual-risk can be screened at peripheral, less-equipped clinics. Syphilis PCR can be easily taken at such clinics, has been shown to be more sensitive than DGM and in addition can be used on oral and anorectal lesions. 5 We suggest that the use of PCR, in combination with serology, particularly in circumstances where DGM does not take place, has the potential to increase the diagnosis of acute syphilis. The identification of syphilis using PCR may in turn reduce the number of those who are falsely reassured by a negative baseline serological test who remain at risk of ongoing transmission. We also know that a proportion of high-risk individuals never attend sexual health clinics and may present to their general practitioner (GP) with ano-genital ulceration. 6 While additional costs may be incurred by the introduction of such an assay, it is important to consider the potential savings made by diagnosing acute syphilis in this fashion. Benefits include avoiding early recall for blood testing in those who are initially DGM or serology negative and treating earlier, thus limiting onward transmission. Individuals with lesions clinically suspicious for primary syphilis are often found to have HSV1 or HSV2 7 and a combined HSV1, HSV2 and T. pallidum PCR assay would help to limit the number of swabs the patient is subject to. Such a multiplex genital ulcer swab can complement syphilis serology and DGM in core GUM clinics but also can be used by both 'hub and spoke' sexual health clinics and GPs irrespective of the availability of DGM. Further evaluation of cost-effectiveness is required before considering implementation of this assay on a wider scale. However, in an era when acute syphilis is on the rise as highlighted by Psutka et al., this sensitive tool could potentially improve our ability to combat this epidemic and increase diagnoses of acute syphilis in wider settings than the clinics observed in the New Zealand study.
